UCB, Amgen say late stage trials for drug candidate to treat osteoporosis meets primary endpoint

Belgian drugmaker UCB (Euronext Brussels: UCB) and biotech firm Amgen (Nasdaq: AMGN) said the late stage trials for their drug to treat osteoporosis has met primary endpoint.

The trial demonstrated a statistically significant difference in favor of investigational bone-forming agent romosozumab, the companies said in a joint statement. First results from the Phase III trials are expected in the first-half of 2016.

The overall subject incidence of adverse events was generally balanced between arms. Adverse events in patients treated with romosozumab were similar to those previously reported and no new safety signals were detected.